Companion diagnostics (CDx) is an in vitro diagnostic (IVD) technique that provides information about the patient's safety and efficacy against a particular therapeutic drug and helps identify groups of patients who can benefit from a therapeutic product. In order to improve the treatment effect, reduce toxic side effects, and achieve precise medical treatment. Companion diagnosis is an important means to achieve precise targeted therapy of tumors. In 2014, the US FDA issued a companion diagnostic guideline that requires treatments for certain diseases to be accompanied by diagnostic products. Although China has not yet introduced relevant regulations, it is one of the mainstream business models that diagnostic companies and pharmaceutical companies have collaborated to develop drugs and accompanying diagnostic products. A few days ago, the wonderful report of experts from various fields in the China Bio-Industry Conference and Precision Medicine and Companion Diagnostics Branch held in Guangzhou on June 11th, 2019, is a good example of this phenomenon. MEDx (Suzhou) has followed the wave of the times, pioneering and innovating, and pioneered the development of companion diagnostic products in China with a number of pharmaceutical companies, and has become a leader in the industry.
As a pharmaceutical company dedicated to the research and development of biomedicine and possessing top-notch technology at home and abroad,BJ Bioscience Inc.is also aiming at the trend and market of precision medicine. At the same time as the development of tumor-targeted antibody drugs, simultaneous co-development of accompanying diagnostic products has been considered. Recently,MEDx (Suzhou) and Boji Biomedical have reached a strategic cooperation on the joint diagnosis of anti-tumor targeted drug BJ-001. The development of this targeted drug has entered the IND declaration stage, and it is expected to begin in the second half of the year. China and the United States have successively carried out clinical research on patients with high targets for cancer such as lung cancer, head and neck cancer and pancreatic cancer.
For this cooperation, Dr. Zhang Haizhou, co-founder and CEO of BJ Bioscience Inc., said:
“We are very pleased to be able to collaborate with the powerful MEDx (Suzhou). By jointly developing high-quality companion diagnostic products, Boji Biomedicine will be able to more accurately integrate potential beneficiaries and obtain better data. Achieve more scientific experimental input, greatly improve the effectiveness of new drugs and the success rate of research and development, thus helping to shorten the overall development process of innovative antibody drugs."
Dr. Zhang Yafei, Chairman and CEO of MEDx (Suzhou) also commented on this:
“MEDx (Suzhou) has always been adhering to the concept of “diagnosis with treatment” to serve the majority of pharmaceutical companies. With integrated translational medicine platform, excellent team management experience and years of accumulation in the field of accompanying diagnosis, we are in the accompanying diagnostic products. The company has accumulated a lot of successful experience in the development and inspection of the group. At present, it has established good partnerships with many well-known pharmaceutical companies at home and abroad. We are very happy to cooperate with Boji Biomedicine. This cooperation will be for both parties. The broader strategic cooperation in the future has laid a solid foundation and helped to promote the precise medical concept of precision medicine and accompanying diagnosis in China."
According to the agreement, MEDx (Suzhou) will provide the establishment of immunohistochemistry (IHC) method for the biomedical tumor candidate drug BJ-001 and simultaneously develop a companion diagnostic kit. The combination of MEDx (Suzhou) and BJ Bioscience Inc. will bring new hope to the precision medicine of cancer patients in China.
About BJ Bioscience Inc.
BJ Bioscience Inc. is a biotechnology company dedicated to the research and development of innovative drugs. It is created by a returnee expert with many years of experience in research and development of innovative drugs, including major national special drug review experts, and has trade secrets. The protected antibody discovery platform and top technology at home and abroad currently mainly develop biopharmaceuticals for tumors and infectious diseases. The company's main research and management team has many years of experience in research and development and management of antibody drugs in domestic and foreign R&D companies and national key scientific research institutions, especially European and American multinational companies. Focusing on the global view of R&D and based on strong capital support, BJ Bioscience Inc. has a global layout of R&D from a global perspective. It also has two R&D laboratories in San Francisco and Hangzhou, China. It can realize a comprehensive collection of talents, technology, management and capital markets, laying a solid foundation for the company's global positioning and development.
About MEDx (Suzhou) Translational Medicine
MEDx (Suzhou) is a transformational medicine center jointly established with QIAGEN in Germany in 2013. It is committed to building the most comprehensive and service-oriented comprehensive translational medicine service platform in China, and has established genomics, proteomics and cell groups. Advanced technology platform such as learning and pathology, and experienced high-quality professional technical team,MEDx (Suzhou) provides biomarker discovery and verification for precision medicine, molecular testing and screening of new drug clinical trial patients, testing Method development and integrated solutions for the development and commercialization of diagnostic kits, and provide clinical testing drug guidance services for patients, is the pioneer and innovator of the overall solution for accurate diagnostic industry.
Scan the qrcode to reading this article on your phone